Barclays Sets $275 Target and FDA Approves AbbVie CLL Regimen
On February 20, Barclays initiated coverage of AbbVie with an Overweight rating and set a $275 price target, citing unrecognized operating leverage potential and upside from proof-of-concept trial successes. The FDA approved AbbVie’s all-oral, fixed-duration VENCLEXTA and acalabrutinib regimen for treatment-naive chronic lymphocytic leukemia after positive Phase 3 AMPLIFY data.
1. Barclays Initiates Coverage
On February 20, Barclays began coverage of AbbVie with an Overweight rating, highlighting expectations of stronger growth than current consensus. The firm established a $275 price target, signaling confidence in the company’s ability to leverage scale across its portfolio.
2. Rationale Behind Price Target
Barclays noted that existing forecasts understate AbbVie’s operating leverage potential, anticipating margin expansion as R&D investments scale. The note emphasized that positive outcomes from any of AbbVie’s proof-of-concept studies could trigger multiple expansion and drive significant upside.
3. FDA Approval for CLL Regimen
The FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib for previously untreated chronic lymphocytic leukemia patients, based on data from the Phase 3 AMPLIFY trial. This marks the first all-oral, fixed-duration regimen in the front-line CLL setting, offering a targeted, time-limited therapy option.
4. Potential Market Impact
The new regimen’s first-line approval could capture significant share of the CLL market, as patients and clinicians seek oral, finite-duration treatments. Successful launch and uptake may add a meaningful revenue stream and support AbbVie’s longer-term growth trajectory.